Ligand Pharmaceuticals | LGND - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Agenus USD 10.56M 13.04M 2025-12
Amgen USD 1.58B 354M 2026-03
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 46.02M 8.84M 2025-12
Baxter International USD 728M 33M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Eli Lilly USD 2.93B 198M 2026-03
Enanta Pharmaceuticals USD -1.05 0.31 2024-12
Enviri Corporation USD 104.1M 10.81M 2025-12
Gilead Sciences USD 1.78B 425M 2025-12
GlaxoSmithKline GBP 2.12B 558M 2026-03
Glaxosmithkline GBP 3.56B 650.29M 2025-12
Heron Therapeutics USD 23.74M 605K 2025-12
Insmed USD 212.48M 26.11M 2025-12
Intrexon USD 10.31M 41K 2024-06
Ionis Pharmaceuticals USD 151M 21M 2026-03
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
Ligand Pharmaceuticals USD 28.45M 8.27M 2025-09
MacroGenics USD 7.94M 1.96M 2025-12
Merck USD 2.67B 180M 2026-03
Pacira USD 83.88M 7.99M 2026-03
Pfizer USD 4.08B 894M 2025-12
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Veracyte USD 43.31M 8.43M 2025-12